SEC Comment Letter 0000000000-24-001396 to Annovis Bio, Inc. (ANVS)
Annovis Bio, Inc.
Date: Feb. 5, 2024 · CIK: 0001477845 · Accession: 0000000000-24-001396
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276814
Letter
United States securities and exchange commission logo February 5, 2024 Maria Maccecchini, Ph.D. President and Chief Executive Officer Annovis Bio, Inc. 101 Lindenwood Drive, Suite 225 Malvern, PA 19355 Re:Annovis Bio, Inc. Registration Statement on Form S-3 Filed February 1, 2024 File No. 333-276814 Dear Maria Maccecchini: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Joan Guilfoyle, Esq.
Show Raw Text
United States securities and exchange commission logo
February 5, 2024
Maria Maccecchini, Ph.D.
President and Chief Executive Officer
Annovis Bio, Inc.
101 Lindenwood Drive, Suite 225
Malvern, PA 19355
Re:Annovis Bio, Inc.
Registration Statement on Form S-3
Filed February 1, 2024
File No. 333-276814
Dear Maria Maccecchini:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Joan Guilfoyle, Esq.